Disease overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. Follicular lymphoma is …

Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20,
was the first monoclonal antibody to be approved for therapeutic use. Treatment with …

Abstract Disease Overview Follicular lymphoma (FL) is generally an indolent B cell
lymphoproliferative disorder of transformed follicular center B cells. FL is characterized by …

Background Patients with advanced-stage, low-tumour-burden follicular lymphoma have
conventionally undergone watchful waiting until disease progression. We assessed whether …

Given that the FcγRIIIa receptor 158V allotype displays a higher affinity for human
immunoglobulin G1 and increased antibody-dependent cellular cytotoxicity, the aim of this …

Phase 2 studies suggest that the monoclonal antibody rituximab may improve the prognosis
of patients with follicular lymphoma (FL) when it is added to chemotherapy. In the current …

Purpose: Although rituximab is now routinely used in the treatment of B-cell non-Hodgkin's
lymphoma, the mechanism of its antitumor effect is not clear. One potential mechanism of …

Background Patients with follicular lymphoma may survive for periods of less than 1 year to
more than 20 years after diagnosis. We used gene-expression profiles of tumor-biopsy …

The combination of cyclophosphamide, vincristine, and prednisone (CVP) is one of several
standard treatment options for advanced follicular lymphoma. This, like similar …

Background Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and
most patients ultimately relapse. Lenalidomide, an immunomodulatory agent, is effective as …